Advertisement
News
Advertisement

Algea Therapies Launches SHIELD VCF System

Thu, 05/23/2013 - 5:12pm
The Associated Press

AUDUBON, Pa.--(BUSINESS WIRE)--May 23, 2013--Algea Therapies, a division of Globus Medical Inc. (NYSE: GMED), committed to finding innovative, minimally invasive solutions that treat pain and restore quality of life, today announced the launch of the SHIELD™ Vertebral Compression Fracture (VCF) System, a next generation fracture management and vertebral augmentation platform for patients with vertebral compression fractures.

“We are excited to announce the US launch of the SHIELD™ VCF System, the first vertebral augmentation implant to guide cement flow into the anterior region of the vertebral body, while significantly decreasing overall cement leakage compared to traditional VCF methods. The system features a new surgical technique involving unipedicular cavity creation, and a novel cement-directing device, the SHIELD™ implant. With this innovative platform technology, Algea is setting a new standard for safer treatment of vertebral compression fractures,” commented Sean Suh, Senior Group Manager of Algea Therapies.

The SHIELD™ VCF System marks a new level of control in the vertebral body augmentation market. The system is engineered with strategic flow openings designed to give the physician control of cement placement and reduce cement leakage. The system includes the C3 Curved Osteotome, a steerable, unipedicular, curving cavity creator with an adjustable blade. This instrument allows physicians to create a central cavity spanning the sagittal midline for balanced cement augmentation. The C3 Curved Osteotome has the ability to steer and navigate around difficult and damaged anatomy, creating cavities to match the anatomical requirements of each fracture.

Indications for Use The SHIELD™ VCF System is intended to provide control of cement flow during injection of PMMA bone cement that has been cleared for use in vertebral augmentation for the treatment of acute, persistently painful (after a minimum of 6 weeks of conservative care), stable, anterior column osteoporotic compression fractures (wedge or concave) of the vertebrae at levels T4 to L5 in the adult spine.

About Algea Therapies
Algea Therapies, a division of Globus Medical (NYSE: GMED), was created to expand the continuum of care for people with pain by developing innovative, minimally invasive interventional therapies that are effective, easy to use, and designed with the patient's quality of life in mind. The spirit of Algea Therapies is fueled by the needs of patients, as well as the physicians who care for them. By remaining patient-focused and customer centric on a daily basis, Algea Therapies truly provides Interventions for Life. Additional information can be accessed at www.algeatherapies.com.

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at www.globusmedical.com.

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading